28.05
price down icon4.17%   -1.22
 
loading

Tg Therapeutics Inc Aktie (TGTX) Neueste Nachrichten

pulisher
Mar 11, 2026

TG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Mar 11, 2026
pulisher
Mar 10, 2026

(TGTX) Risk Channels and Responsive Allocation - Stock Traders Daily

Mar 10, 2026
pulisher
Mar 10, 2026

Briumvi momentum leads to strong execution for TG Therapeutics (TGTX) - MSN

Mar 10, 2026
pulisher
Mar 10, 2026

BRIUMVI Momentum Leads to Strong Execution for TG Therapeutics (TGTX) - Yahoo Finance

Mar 10, 2026
pulisher
Mar 10, 2026

WINTON GROUP Ltd Buys 113,951 Shares of TG Therapeutics, Inc. $TGTX - MarketBeat

Mar 10, 2026
pulisher
Mar 10, 2026

TG Therapeutics to present BRIUMVI data at neurology meeting - Investing.com Nigeria

Mar 10, 2026
pulisher
Mar 09, 2026

10 Most Shorted Biotech Stocks to Buy According to Hedge Funds - Insider Monkey

Mar 09, 2026
pulisher
Mar 09, 2026

Is TG Therapeutics (TGTX) Pricing Reflecting Its Mixed Multi Year Share Performance? - Yahoo Finance

Mar 09, 2026
pulisher
Mar 09, 2026

TGTX: Positive Phase 3 Analysis Results for Briumvi in Treating Multiple Sclerosis - GuruFocus

Mar 09, 2026
pulisher
Mar 09, 2026

MS patients on BRIUMVI saw far fewer relapses and brain lesions - Stock Titan

Mar 09, 2026
pulisher
Mar 09, 2026

Bank of America Securities bearish on TG Therapeutics (TGTX) post earnings - MSN

Mar 09, 2026
pulisher
Mar 09, 2026

The Bull Case For TG Therapeutics (TGTX) Could Change Following New Azer-cel Milestone In Progressive MS - Sahm

Mar 09, 2026
pulisher
Mar 08, 2026

How Investors Are Reacting To TG Therapeutics (TGTX) Adding Azer-cel Milestone to Its MS Portfolio - Yahoo Finance

Mar 08, 2026
pulisher
Mar 08, 2026

Azer Cel Milestone Broadens TG Therapeutics Autoimmune Pipeline And Valuation Story - Yahoo Finance

Mar 08, 2026
pulisher
Mar 08, 2026

Assessing TG Therapeutics (TGTX) Valuation After BRIUMVI‑Led Earnings And Autoimmune Pipeline Updates - Yahoo Finance

Mar 08, 2026
pulisher
Mar 08, 2026

Bank of America Securities Bearish on TG Therapeutics (TGTX) Post Earnings - Finviz

Mar 08, 2026
pulisher
Mar 07, 2026

Is TG Therapeutics Inc. (NKB2) stock included in top ETFs2026 Buyback Activity & AI Forecast Swing Trade Picks - Naître et grandir

Mar 07, 2026
pulisher
Mar 07, 2026

TG Therapeutics to present BRIUMVI data at neurology meeting By Investing.com - Investing.com Canada

Mar 07, 2026
pulisher
Mar 06, 2026

TG Therapeutics (TGTX) sees price target drop from JPMorgan - MSN

Mar 06, 2026
pulisher
Mar 06, 2026

TG Therapeutics, Inc. $TGTX Stake Cut by Teachers Retirement System of The State of Kentucky - MarketBeat

Mar 06, 2026
pulisher
Mar 06, 2026

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting - Bitget

Mar 06, 2026
pulisher
Mar 06, 2026

What researchers will share on BRIUMVI in multiple sclerosis at AAN 2026 - Stock Titan

Mar 06, 2026
pulisher
Mar 06, 2026

TG Therapeutics Azer Cel Milestone Adds Depth To Autoimmune Valuation Story - Sahm

Mar 06, 2026
pulisher
Mar 06, 2026

Reports Suggest TG Therapeutics May Be Scaling Back Operations Amid Speculation on CafePharma Forum - geneonline.com

Mar 06, 2026
pulisher
Mar 05, 2026

TG Therapeutics Q2 EPS Estimate Lowered by HC Wainwright - MarketBeat

Mar 05, 2026
pulisher
Mar 04, 2026

TG Therapeutics Q4 EPS Forecast Lowered by HC Wainwright - MarketBeat

Mar 04, 2026
pulisher
Mar 03, 2026

TG Therapeutics Confronts Rising AI Regulatory and IP Risks That Could Pressure Costs, Strategy, and Growth - The Globe and Mail

Mar 03, 2026
pulisher
Mar 02, 2026

Precision BioSciences (DTIL) Hits Milestone, Secures $7.5M from TG Therapeutics - GuruFocus

Mar 02, 2026
pulisher
Mar 02, 2026

TG Therapeutics, Inc. (TGTX) Growth Potential: Navigating A 47.65% Upside In Biotech - DirectorsTalk Interviews

Mar 02, 2026
pulisher
Mar 02, 2026

Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis - Yahoo Finance

Mar 02, 2026
pulisher
Mar 02, 2026

HC Wainwright Raises Earnings Estimates for TG Therapeutics - MarketBeat

Mar 02, 2026
pulisher
Mar 01, 2026

Is TG Therapeutics’ 2025 Earnings Miss and BRIUMVI Guidance Shift Altering The Investment Case For TGTX? - simplywall.st

Mar 01, 2026
pulisher
Mar 01, 2026

TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2025 Earnings Call Transcript - Insider Monkey

Mar 01, 2026
pulisher
Mar 01, 2026

TG Therapeutics (TGTX) Reports Financial Results for Q4 and Full Year 2025 - Finviz

Mar 01, 2026
pulisher
Feb 28, 2026

TG Therapeutics (TGTX) Earnings Spark Debate As 72.6% Net Margin Defies Forecast Narratives - Sahm

Feb 28, 2026
pulisher
Feb 28, 2026

TG Therapeutics Five Year Briumvi Data Highlights Durable Efficacy And Valuation Gap - Sahm

Feb 28, 2026
pulisher
Feb 28, 2026

TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line - The Globe and Mail

Feb 28, 2026
pulisher
Feb 28, 2026

Decoding TG Therapeutics Inc (TGTX): A Strategic SWOT Insight - GuruFocus

Feb 28, 2026
pulisher
Feb 28, 2026

TGTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Feb 28, 2026
pulisher
Feb 27, 2026

TG Therapeutics Five Year BRIUMVI Data And What It Means For Valuation - Yahoo Finance

Feb 27, 2026
pulisher
Feb 27, 2026

TG Therapeutics (NASDAQ:TGTX) Announces Quarterly Earnings Results, Misses Expectations By $0.21 EPS - MarketBeat

Feb 27, 2026
pulisher
Feb 27, 2026

TG THERAPEUTICS, INC. SEC 10-K Report - TradingView

Feb 27, 2026
pulisher
Feb 27, 2026

TG Therapeutics: "Strong Buy" On BRIUMVI's Massive Growth And Possible Expansion (TGTX) - Seeking Alpha

Feb 27, 2026
pulisher
Feb 27, 2026

(TGTX) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Feb 27, 2026
pulisher
Feb 27, 2026

TG Therapeutics Experiences Evaluation Revision Amidst Evolving Market Dynamics - Markets Mojo

Feb 27, 2026
pulisher
Feb 27, 2026

TG Therapeutics Q4 Earnings Call Highlights - MarketBeat

Feb 27, 2026
pulisher
Feb 27, 2026

Q1 EPS Estimates for TG Therapeutics Raised by HC Wainwright - MarketBeat

Feb 27, 2026
pulisher
Feb 26, 2026

TG Therapeutics: Q4 Earnings Snapshot - theheraldreview.com

Feb 26, 2026
pulisher
Feb 26, 2026

TG Therapeutics (TGTX) Q4 2025 Earnings Transcript - The Globe and Mail

Feb 26, 2026
pulisher
Feb 26, 2026

Earnings call transcript: TG Therapeutics Q4 2025 earnings miss EPS expectations - Investing.com

Feb 26, 2026
pulisher
Feb 26, 2026

TG Therapeutics (TGTX) Misses Q4 Earnings Estimates - Yahoo! Finance Canada

Feb 26, 2026
pulisher
Feb 26, 2026

TG Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 26, 2026
pulisher
Feb 26, 2026

TG Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com

Feb 26, 2026
pulisher
Feb 26, 2026

TG Therapeutics: Fourth Quarter Financial Highlights - Bitget

Feb 26, 2026
pulisher
Feb 26, 2026

TG THERAPEUTICS INC (NASDAQ:TGTX) Q4 2025 Earnings Miss Estimates Despite Strong BRIUMVI Outlook - ChartMill

Feb 26, 2026
pulisher
Feb 26, 2026

TG Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance

Feb 26, 2026
pulisher
Feb 26, 2026

TG Therapeutics (TGTX) Reports Q4 Earnings Miss - GuruFocus

Feb 26, 2026
pulisher
Feb 26, 2026

TG Therapeutics Q4 Earnings Fall, Revenue Rises; Issues 2026 Revenue Guidance; Shares Down Pre-bell - marketscreener.com

Feb 26, 2026
pulisher
Feb 26, 2026

Earnings Flash (TGTX) TG Therapeutics Posts Q4 EPS $0.14, vs. FactSet Est of $0.35 - marketscreener.com

Feb 26, 2026
pulisher
Feb 26, 2026

TGTX Projects Strong Financial Performance Through 2026 - GuruFocus

Feb 26, 2026
pulisher
Feb 26, 2026

TGTX Financial Health and Future Funding Outlook - GuruFocus

Feb 26, 2026
pulisher
Feb 26, 2026

TG THERAPEUTICS ($TGTX) Releases Q4 2025 Earnings - Quiver Quantitative

Feb 26, 2026
$46.69
price up icon 1.57%
$29.58
price down icon 0.40%
$55.97
price up icon 1.80%
$90.84
price up icon 8.28%
$139.40
price down icon 3.09%
biotechnology ONC
$298.91
price down icon 2.12%
Kapitalisierung:     |  Volumen (24h):